



(51) International Patent Classification:

*A61K 9/00* (2006.01) *A61K 9/51* (2006.01)  
*A61N 5/10* (2006.01) *A61K 33/24* (2006.01)

(21) International Application Number:

PCT/EP2016/061989

(22) International Filing Date:

27 May 2016 (27.05.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

EP15305810.2 28 May 2015 (28.05.2015) EP

(71) Applicant: **NANOBIOTIX** [FR/FR]; 60 rue de Wattignies, 75012 Paris (FR).

(72) Inventors: **MARILL, Julie**; 8 rue des Pontons, 94140 Alfortville (FR). **POTTIER, Agnès**; 6 rue Sainte Beuve, 75006 Paris (FR). **LEVY, Laurent**; 246 Boulevard Raspail, 75014 Paris (FR).

(74) Agent: **CABINET BECKER ET ASSOCIES**; 25, rue Louis le Grand, 75002 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINE

(57) Abstract: The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.



WO 2016/189125 A1

**NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINE.****FIELD OF THE INVENTION**

5           The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine, as such or included in a composition, in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer. The nanoparticles whose use is herein described consist in a material having a density of at least 7 g/cm<sup>3</sup> and an atomic number (Z) of at least 25. Each nanoparticle is covered with a biocompatible coating allowing its stability between pH 6.5 and 7.5 in a physiological fluid. When irradiated, these nanoparticles are capable of boosting the destruction of cancer cells thanks to an optimized stimulation of the subject's own immune system when compared to the cancer cells' destruction obtained with radiotherapy alone, in particular in a subject suffering from a metastatic cancer, preferably in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, in a subject suffering from a cancer which is not (conventionally) treated by radiotherapy, and in a subject suffering from a liquid cancer. Thanks to the present invention, irradiation doses administered to the subject in the context of radiotherapy, preferably in the context of a fractionated radiotherapy, are significantly more efficient in terms of cancer cell destruction without adversely affecting surrounding healthy tissue more. The present description in addition discloses new compositions and kits as well as uses thereof.

**BACKGROUND**

25       Cancer is a leading cause of death worldwide, which accounted for 8.2 million deaths in 2012. It is expected that annual cancer cases will rise from 14 million in 2012 to 22 within the next two decades (WHO). Cancer may grow locally and/or spread systemically through lymphatic or hematogenous routes.

30       Surgery, radiation therapy, and pharmaceuticals, in particular chemotherapeutic drugs, are of central importance in the treatment of cancer, each of which can be used alone or in combination, to address all sites at risk for harboring disease, depending on the type of cancer being treated. For a malignancy to be cured, it must be controlled at both the local and systemic levels.

35       In spite of recent advances in the detection and treatment of some malignancies, metastases remain common and account for approximately 80-90% of cancer deaths. The standard treatment for metastatic disease in most patient cancers is systemic cytotoxic chemotherapy and hormonal deprivation (Dhara M. MacDermid et al. Journal of Surgical Oncology 2008). There is a vital need for the development of novel curative therapies for the treatment of patients with metastatic cancer.

Some specific tumors/cancers have an affinity to spread to selected organs. The most common sites of metastases are lungs (e.g. when the primary cancer is a sarcoma), liver (e.g. .g. when the primary cancer is a gastrointestinal cancer), bones (e.g. .g. when the primary cancer is a breast or a prostate cancer) and the brain (e.g. .g. when the primary cancer is a lung cancer, a renal cancer, or a melanoma).

Radiotherapy is the second most used treatment of cancer, ahead of pharmaceuticals, with an estimated half of all newly diagnosed cancer patients receiving radiotherapy at some point in the course of their disease. Radiation therapy uses high-energy particles or waves, such as X-rays, gamma rays, electron beams, or protons, to destroy or damage cancer cells.

The therapeutic use of local ionizing radiation has been largely guided by a strategy designed to achieve the goal of effectively eliminating cancer cells. Radiotherapy as a sole therapeutic modality can offer the possibility for organ functional preservation, such as in the context of bladder and laryngeal cancers. As an adjuvant therapy, radiotherapy can facilitate resection when given before surgery, or treat microscopic residual disease when given after surgery, such as treatment after breast-conserving lumpectomy. A new development is the use of stereotactic body radiotherapy (SBRT) to ablate sites of oligometastatic disease. SBRT enables highly focal treatment of cancer with single or few fractions of high-dose radiations (typically between 5 Gy and 25 Gy). The existence of an oligometastatic state is based on an “intermediate between purely localized lesions and those widely metastatic”. Typically between 1 up to 5, for example 1, 2, 3, 4 or 5, metastases or metastatic lesions are considered for SBRT (Dhara M. MacDermid et al. Journal of Surgical Oncology 2008; Ralph R. Weichselbaum Nat. Rev. Clin. Oncol. 2011).

However, metastatic malignancies with many distant metastases (typically more than 5, preferably more than 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 metastases) are associated with a poor prognosis (Ralph R. Weichselbaum Nat. Rev. Clin. Oncol. 2011).

Patients with widespread systemic diseases (patients exhibiting many metastases also identified as “polymetastatic” patients) are typically not considered by the oncologist as curable by current regional treatment such as radiotherapy. On the other hand, palliative radiotherapy is used for palliation of symptoms and is distinct from radiotherapy delivered as curative treatment (Sonam Sharma et al. Seminars in Oncology 2014). Palliative radiotherapy is an efficacious treatment for many symptoms from locally advanced or metastatic tumors, even for patients with short life expectancy (Sonam Sharma et al. Seminars in Oncology 2014). Here, radiotherapy can be an effective treatment for pain, neurologic symptoms, relief of obstructive symptoms (such as biliary or urinary tract obstructions) and relief from bleeding or ulcerated lesions. Palliative radiotherapy may also be used to assist with maintenance of local tumor control in area likely to be affected and become symptomatic. Typical dose-fractionation schemes in palliative radiotherapy are the followings:

- $1 \times 8$  Gy,  $5-6 \times 4$  Gy,  $10 \times 3$  Gy for uncomplicated bone metastases and for 1 day up to 2 weeks;
- $5 \times 4$  Gy;  $10 \times 3$  Gy,  $15 \times 2.5$  Gy for whole brain radiotherapy and for 1 up to 3 weeks;

- 2 × 7.5-8.5 Gy, 10 × 3 Gy, 15 × 2.5 Gy for advanced cancer in lung causing airway obstruction, superior vena cava syndrome and for 1 up to 3 weeks;

- 1 × 8-10 Gy, 5 × 4 Gy, 10 × 3 Gy, 15-30 × 2-3 Gy for visceral metastases causing pain, symptoms of obstruction, bleeding and for 1 day up to 6 weeks;

- 5 - 1- 5 × 6-24 Gy for stereotactic radiotherapy generally reserved for patients with good performance status, with expected long prognosis and/or with few metastases and for 1 up to 5 days (Sonam Sharma et al. Seminars in Oncology 2014, Table 3).

Besides, available evidence suggests that local radiation at clinically therapeutic doses elicits some activation of the innate and adaptive immune system. Radiation has been shown to induce an immunogenic cell death (ICD), potentially converting a tumor into *in situ* vaccine, characterized in particular by three molecular signals that promote uptake of dying cells by dendritic cells, cross-  
10 presentation of the tumor-derived antigens to T cells, and activation of anti-tumor T cells including activation of cytotoxic CD8+ T cells: exposure of calreticulin (CRT) on the tumor cell surface, release of high-mobility group protein B1 (HMGB1), and release of ATP (Oliver Kepp et al.  
15 Oncoimmunology 2014).

It is also known that tumor response to radiations includes DNA damages and that sensing of tumor-derived DNA may trigger IFN production and generate anti-tumor T-cell responses to immunogenic tumors (see for instance Theresa L. Whiteside et al. 2016).

Radiation is a complex modifier of tumor microenvironment and, by itself, is seldom sufficient to  
20 induce a therapeutically significant anti-tumor immune response, since it can also detrimentally activate immune suppressive pathway. The proportion of tumor cells undergoing ICD and the remodeling of tumor microenvironment after radiation are variable. The results of this balance ultimately determine the ability of radiation to convert dying cancer cells into an effective *in situ* vaccine (Sandra Demaria and Silvia C. Formenti, 2012).

25 Combinations of radiation with immunotherapeutic agents have been reported to stimulate the immune response. Cytokines [interleukin-2 (IL2) and interferon-alpha (IFN $\alpha$ )] have been used for decades as therapeutic approach. Today, numerous strategies for overcoming tumor immune evasion are under evaluation. Example of immunotherapeutic approaches under clinical evaluation include (1) T-cell checkpoint inhibitors or agonists for T-cell activation pathway (2) novel cytokines such as IL12  
30 and IL15, (3) therapeutic vaccine, (4) elimination of immunosuppressive cells and (5) other agents and approaches designed to enhance immune cell function (Scott J. Antonia et al. 2014; Theresa L. Whiteside et al. 2016).

However, producing effective treatment vaccines remains difficult and challenging. To be effective, cancer treatment vaccines must achieve two goals. First, they must stimulate specific immune  
35 responses against the correct target cells (i.e. cancer cells). Second, the immune responses must be powerful enough to overcome the barriers that these cells use to protect themselves from attack by the host immune systems, typically by B cells and natural killer T cells.

## SUMMARY OF THE INVENTION

Inventors now herein describe the advantageous use of a nanoparticle and/or aggregate of nanoparticles as a therapeutic vaccine, as such or included in a composition (which is typically a therapeutic composition, in particular a vaccine composition), in a subject suffering of a cancer and exposed to radiotherapy. The nanoparticle and/or aggregate of nanoparticles as well as the composition comprising a nanoparticle and/or aggregate of nanoparticles is typically for use for treating cancer. The combination of such nanoparticles with radiotherapy significantly enhances the host's anti-cancer immune response and optimizes the global treatment, in particular in the context of a fractioned radiotherapy comprising at least one irradiation step wherein the ionizing radiation dose ranges from 1.8 to 30 Gray (Gy), preferably 1.8 to 20 Gray (Gy), typically from 2 to 15 Gray (Gy). The present invention is particularly efficient towards metastatic cancer when the cancer has evolved into a widespread systemic disease (as defined herein above) thanks to the abscopal effect allowed by the technology, and towards liquid cancer, and favors a complete and permanent anti-tumor activity.

The abscopal effect is a phenomenon observed in the treatment of metastatic cancer where localized irradiation of a particular tumor site causes a response in a site distant to the irradiated volume. Radiotherapy may help reverse the tolerance to weakly immunogenic tumour-associated antigens in order to elicit an anticancer immune response. However, the abscopal effect has remained a rare clinical event when radiotherapy is used alone. Kobe Reynders et al. reported 23 clinical cases of abscopal affect after radiotherapy between 1973 and 2013 (Kobe Reynders et al. Cancer Treatment Review 2015).

Thanks to the present invention local irradiation is able to elicit the development of a sustained anti-tumor response when compared to radiotherapy alone thereby enhancing the control of the tumor both locally and systemically.

Examples herein provided for the first time by inventors demonstrate the *in vitro* amplification of damage associated molecular patterns (DAMPs) induced by dying cancer cells [the herein tested cancer cell lines including radiosensitive cell lines (such as the human colorectal HCT 116 cancer cell line) and radioresistant cell lines (such as the human glioblastoma 42 MG BA cell line or the human pancreas PANC-1 cancer cell line)] when using the nanoparticle and/or aggregate of nanoparticles as a therapeutic vaccine.

Of upmost interest, vaccination of immunocompetent mice with murine colorectal CT-26 cancer cell treated with the nanoparticles and/or aggregates of nanoparticles of the present invention and irradiated *in vitro*, markedly prevent the formation of a tumor when the animal are challenged 7 days later with healthy/living CT-26 cancer cells, when compared to radiotherapy alone. Such results surprisingly demonstrate that the combination of nanoparticles of the invention with radiotherapy

amplify the immune response and transform dying cancer cells into an efficient vaccine directed against cancer cells.

In a preferred aspect, the herein described products of the invention (nanoparticle and/or aggregate of nanoparticles and compositions comprising such a nanoparticle and/or aggregate of nanoparticles) are preferably for use in a subject selected from a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, a subject suffering from a cancer which is not (conventionally) treated by radiotherapy, and a subject suffering from a liquid cancer, and are preferably for use in a subject selected from a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, and a subject suffering from a liquid cancer.

The subject suffering from a metastatic cancer is typically a subject as herein defined suffering of a cancer having many distant metastases which has typically evolved into a widespread systemic disease. Subjects having many distant metastases are also herein identified as a “polymetastatic” subject or patient.

Herein described is thus a nanoparticle and/or aggregate of nanoparticles for use as a therapeutic vaccine, or a nanoparticle and/or aggregate of nanoparticles for use for preparing a therapeutic composition, typically a vaccine composition, for use (typically for use for treating cancer) in a subject suffering from a cancer, typically from a metastatic cancer [metastatic cancer being herein typically defined as involving many/numerous distant metastases and being typically considered as associated to a widespread systemic disease], from a cancer which is not (conventionally) treated by radiotherapy, or from a liquid cancer, in the context of fractionated radiotherapy comprising at least one irradiation step wherein the ionizing radiation dose ranges from 1.8 to 30 Gray (Gy), preferably 1.8 to 20 Gray (Gy), typically from 2 to 15 Gray (Gy), and wherein each nanoparticle consists in a material having a density of at least  $7 \text{ g/cm}^3$  and an atomic number (Z) of at least 25, and each nanoparticle or aggregate of nanoparticles is covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid.

The nanoparticle and/or aggregate of nanoparticles is typically for use for treating cancer, preferably in a selected population of subjects/patients, typically in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, in a subject suffering from a cancer which is not (conventionally) treated by radiotherapy, or in a subject suffering from a liquid cancer.

Also herein disclosed is a vaccine composition for use, typically for use for treating cancer, in a subject suffering from cancer, typically from a metastatic cancer (in particular a metastatic cancer

where cancer has evolved into a widespread systemic disease), or from a liquid cancer, in the context of radiotherapy, preferably in the context of a fractionated radiotherapy.

A typical composition is a vaccine composition comprising a nanoparticle and/or aggregate of nanoparticles for use for treating cancer in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, in a subject suffering from a cancer which is not (conventionally) treated by radiotherapy, or in a subject suffering from a liquid cancer, wherein the treatment comprises exposing the subject to a fractionated radiotherapy comprising at least one irradiation step wherein the ionizing radiations dose ranges from 1.8 to 30 Gray (Gy), preferably 1.8 to 20 Gray (Gy), and wherein each nanoparticle consists in a material having a density of at least 7 g/cm<sup>3</sup> and an atomic number (Z) of at least 25 and each nanoparticle or aggregate of nanoparticles is covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid.

The vaccine composition comprises a nanoparticle or aggregate of nanoparticles as herein described preferably together with a pharmaceutically acceptable carrier or vehicle. A particular vaccine composition further comprises at least one immunotherapeutic agent and optionally a therapeutic agent for treating cancer.

Also herein described is the use of a nanoparticle or aggregate of nanoparticles or a therapeutic composition as herein defined for treating cancer in a subject, preferably in selected populations of subjects/patients, typically in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, in a subject suffering from a cancer which is not (conventionally) treated by radiotherapy, or in a subject suffering from a liquid cancer, as well as the corresponding methods for treating cancer in a subject in need thereof comprising a step of administering to said subject a nanoparticle or aggregate of nanoparticles or a therapeutic composition as herein defined.

Further herein provided is a kit, typically a vaccine kit, comprising (i) a nanoparticle or aggregate of nanoparticles as herein described, or a composition comprising such a nanoparticle or aggregate of nanoparticles, preferably together with (ii) at least one immunotherapeutic agent and/or therapeutic agent for treating cancer.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1:** HMGB1 released in the concentrated cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticles (NPs) suspension from example 1 and exposed or not to radiotherapy (5 Gy delivered in a single fraction) is reported as fold-change in comparison to untreated control.

**Figure 2:** HMGB1 released in the concentrated cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticles (NPs) suspension from example 1 and exposed or not to radiotherapy (10 Gy delivered in a single fraction) is reported as fold-change in comparison to untreated control.

**Figure 3:** HMGB1 released in the cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticles (NPs) suspension from example 1 and exposed or not to radiotherapy delivered in a single fraction is reported as fold-change in comparison to untreated control. A) the cancer cell line is the HCT 116 human colorectal cell line and the irradiation doses correspond to 4 Gy and 6 Gy; B) the cancer cell line is the 42 MG BA human glioblastoma cell line and the irradiation doses correspond to 10 Gy and 15 Gy; C) the cancer cell line is the PANC-1 human pancreas cell line and the irradiation dose corresponds to 8 Gy.

It is well known to adapt *in vitro* the dose (delivered in a single fraction) to the radiosensitivity of the cancer cells. Radiosensitive cancer cell line such as the HCT 116 cell line may receive lower radiation dose when compared to more radio resistant cancer cell lines such as the 42 MG BA and the PANC-1 cell lines. The increased generation of DAMPs observed *in vitro* anticipates an enhance immune response *in vivo*.

**Figure 4:** ATP secretion from HCT 116 cancer cells treated or not with HfO<sub>2</sub> nanoparticles (NPs) suspension from example 1 and exposed or not to radiotherapy (6 Gy delivered in a single fraction) is reported as fold-change in comparison to untreated control.

**Figure 5:** Illustration of the vaccination assay protocol performed with the murine colorectal CT-26 cell line in immunocompetent mice, presenting the schedule of injection for the three groups, group 1 (control group), group 2 (irradiation group: 6 Gy delivered in a single fraction) and group 3 (HfO<sub>2</sub> NPs from example 1 exposed to irradiation: 6 Gy delivered in a single fraction)

**Figure 6:** vaccination assay protocol where the percentage of tumor free mice for group 1 (control), group 2 (RTx, 6 Gy) and group 3 (HfO<sub>2</sub> NP example 1 + RTx, 6 Gy) is presented as function of the days post vaccination.

## DETAILED DESCRIPTION OF THE INVENTION

### *Radiotherapy*

Nanoparticle and/or aggregate of nanoparticles as well as any composition comprising such nanoparticle and/or aggregate of nanoparticles are herein described for use as a therapeutic composition or vaccine (composition) in a subject suffering from a cancer, in particular from a metastatic cancer, preferably from a metastatic cancer where cancer has evolved into a widespread systemic disease, or from a liquid cancer, in the context of radiotherapy, i.e. in a subject to whom nanoparticles have been administered and who is then exposed to radiotherapy. In other words to



become usable as a therapeutic vaccine, nanoparticles are to be exposed to ionizing radiations which means that they are used in combination with radiotherapy.

A cancer which has evolved into a widespread systemic disease typically involves many distant metastases, typically more than 5, preferably more than 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 metastases, and is most of the time associated with a poor prognosis (cf. Ralph R. Weichselbaum Nat. Rev. Clin. Oncol. 2011). The subject suffering from such a cancer may further comprise in addition to the metastatic lesions/sites associated to said cancer other cancer cells sites/lesions which are primary and/or metastatic cancer lesions associated to a distinct primary cancer/tumor.

A particular composition herein described is a vaccine composition comprising a nanoparticle and/or aggregate of nanoparticles for use for treating cancer in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom radiotherapy has been abandoned (typically has been abandoned as a (global) curative treatment), in a subject suffering from a cancer which is not (conventionally/classically) treated by radiotherapy, or in a subject suffering from a liquid cancer, wherein the treatment comprises exposing the subject to a fractionated radiotherapy comprising at least one irradiation step wherein the ionizing radiations dose ranges from 1.8 to 30 Gray (Gy), preferably 1.8 to 20 Gray (Gy), and wherein each nanoparticle consists in a material having a density of at least 7 g/cm<sup>3</sup> and an atomic number (Z) of at least 25 and each nanoparticle or aggregate of nanoparticles is covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid.

In the context of the present invention, the subject or patient is a mammal. In a particular embodiment, the mammal is a human being, whatever its age or sex. The subject suffers from a cancer.

A preferred subject likely to benefit from the invention typically suffers from a solid cancer or from a liquid cancer.

In a particular aspect, the subject suffers from a cancer classically treated by radiotherapy or where radiotherapy is a classical treatment or is the most appropriate treatment for a particular subject, or where radiotherapy could be indicated.

In another particular and preferred aspect, the subject who will benefit from the present invention is a subject who suffers from a cancer where radiotherapy would not be considered as a treatment option (or in other words is not considered as a conventional treatment or possible curative treatment for the considered subject, or is only used against one or a few, typically less than five cancer cells sites/lesions, said lesions being metastatic or primary cancer lesions among numerous cancer cells sites/lesions present in the subject) or would no longer be considered as a (curative) treatment option, typically when the subject is under palliative treatment or when radiotherapy was abandoned. When

under palliative treatment, the subject is still exposed to radiotherapy but said radiotherapy can no longer be considered as a curative radiotherapy.

In this context, the subject is preferably a subject suffering from a metastatic cancer with many/numerous and distant metastases (i.e. widespread metastases), typically more than 5, preferably

more than 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 metastases, as explained previously. In other words, the nanoparticles and/or aggregates of nanoparticles of the present invention, when exposed to ionizing radiations, could offer a solution to patients' populations for which radiotherapy is not considered by the oncologist as a curative treatment.

The present invention now offers to such particular subjects a curative cancer treatment option.

A typical subject suffering from a cancer likely to benefit from the invention is selected from a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, a subject suffering from a cancer which is not (conventionally/classically) treated by radiotherapy, and a subject suffering from a liquid cancer. Preferably the subject is selected from a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, and a subject suffering from a liquid cancer.

In the art and in the context of the present invention, the term "curative treatment" or "curative therapy" refers to a treatment or therapy, in particular "radiotherapy", offering to the subject to be treated a curative solution for treating the cancer(s) he/she is affected by, that is for globally treating said subject [primary tumor(s) as well as corresponding metastatic lesion(s)].

As well known by the skilled person, palliative radiotherapy is used for palliation of symptoms and is distinct from radiotherapy, i.e. radiotherapy delivered as curative treatment (also herein identified as "curative radiotherapy"). Indeed, palliative radiotherapy is considered by the skilled person as an efficacious treatment for treating many symptoms induced by locally advanced or metastatic tumors, even for patients with short life expectancy.

Typically, the metastatic cancer affects (i) a connective tissue and is preferably selected from a fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, malignant fibrous histiocyoma, (ii) an endothelium or mesothelium tissue and is preferably selected from hemangiosarcoma, angiosarcoma, lymphangiosarcoma and mesothelioma, (iii) a muscle tissue and is preferably selected from leiomyosarcoma and rhabdomyosarcoma, (iv) an epithelial tissue and is preferably selected from adenocarcinoma, squamous cell carcinoma and epidermoid carcinoma, (v) a neural tissue and is preferably selected from multiform glioblastoma, glioma, neuroblastoma, medulloblastoma, meningioma, neurofibrosarcoma and schwannoma, and (vi) the APUD system and

is preferably selected from thyroid carcinoma, pancreas carcinoma, stomach carcinoma and intestine carcinoma. In another preferred embodiment, the metastatic cancer is a melanoma.

The metastatic cancer can be, or can derive from, a cancer selected for example from skin cancer, central nervous system cancer, head and neck cancer, lung cancer, kidney cancer, breast cancer, gastrointestinal cancer (GIST), prostate cancer, liver cancer, colon cancer, rectum cancer, anal cancer, oesophagus cancer, male genitourinary cancer, gynecologic cancer, adrenal and retroperitoneal cancer, sarcomas of bone and soft tissue, pediatric cancer, neuroblastoma, central nervous system cancer and Ewing's sarcoma.

Typically, the liquid cancer affects blood or lymphoid cell tissue. It is typically selected from leukemia, myeloma and lymphoma.

The subject may have a tumor. Unless otherwise specified in the present disclosure, the tumor is a malignant tumor.

In another embodiment, the subject suffers from a liquid cancer where radiotherapy is indicated by the oncologist (for example lymphoma).

Preferably the radiotherapy the subject is to be exposed to is a fractionated radiotherapy, advantageously a fractionated radiotherapy comprising at least one irradiation step (also herein identified as a "fraction treatment"), typically several irradiation steps, wherein the ionizing radiations dose ranges from 1.8 to 30 Gray (Gy), preferably 1.8 to 20 Gray (Gy), preferably from 1.8 to 15 Gray (Gy), per irradiation step.

In the context of a fractionated radiotherapy the total dose of ionizing radiations is divided into several, smaller doses over a period of several days. This maximizes the effect of radiations on cancer and minimizes the negative side effects on healthy cells. Typical fractionation schemes divide the total dose into 30 units/fractions delivered every weekday over 6 weeks, though current research is considering the benefits of accelerated fractionation (2 deliveries per day and/or deliveries on weekends as well).

The term "Ionizing radiations" refers to highly-energetic particles or waves that can ionize an atom or molecule. Ionizing ability depends on the energy of individual particles or waves, and not on their number. A large flood of particles or waves will not, in the most-common situations, cause ionization if the individual particles or waves are insufficiently energetic. A typical ionizing radiation is a radiation, the energy of which is of at least 1.8 KeV.

In a preferred embodiment, the ionizing radiations dose per irradiation step is selected from 1.8, 2, 2.2, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 20, 25 and 30 Gy per fraction treatment. The ionizing radiations dose is preferably selected from 1.8, 2, 2.4, 2.5, 3, 3.2, 3.6, 4, 4.5, 5,

5.5, 6, 7, 8, 10, 15, 20, 25 and 30 Gy per fraction treatment, even more preferably from 2, 3, 5, 6, 7, 8, 10, 15, 20, 25 and 30 Gy.

Preferred fractionated radiotherapy can be selected from 25 fractions of 2 Gy (total: 50 Gy), 30 fractions of 2 Gy (total: 60 Gy), 35 fractions of 2 Gy (total: 70 Gy), 40 fractions of 2 Gy (total: 80 Gy), 5 fractions of 3 Gy (total: 15 Gy), 10 fractions of 3 Gy (total: 30 Gy), 15 fractions of 3 Gy (total: 45 Gy), 20 fractions of 3 Gy (total: 60 Gy), 25 fractions of 3 Gy (total: 75 Gy), 3 fractions of 4 Gy (total: 12 Gy), 5 fractions of 4 Gy (total: 20 Gy), 8 fractions of 4 Gy (total: 32 Gy), 10 fractions of 4 Gy (total: 40 Gy), 15 fractions of 4 Gy (total: 60 Gy), 20 fractions of 4 Gy (total: 80 Gy), 2 fractions of 5 Gy (total: 10 Gy), 3 fractions of 5 Gy (total: 15 Gy), 4 fractions of 5 Gy (total: 20 Gy), 5 fractions of 5 Gy (total: 25 Gy), 6 fractions of 5 Gy (total: 30 Gy), 8 fractions of 5 Gy (total: 40 Gy), 10 fractions of 5 Gy (total: 50 Gy), 1 fraction of 6 Gy (total: 6 Gy), 2 fractions of 6 Gy (total: 12 Gy), 3 fractions of 6 Gy (total: 18 Gy), 4 fractions of 6 Gy (total: 24 Gy), 5 fractions of 6 Gy (total: 30 Gy), 6 fractions of 6 Gy (total: 36 Gy), 10 fractions of 6 Gy (total: 60 Gy), 1 fraction of 7 Gy (total: 7 Gy), 2 fractions of 7 Gy (total: 14 Gy), 3 fractions of 7 Gy (total: 21 Gy), 4 fractions of 7 Gy (total: 28 Gy), 5 fractions of 7 Gy (total: 35 Gy), 1 fraction of 8 Gy (total: 8 Gy), 2 fractions of 8 Gy (total: 16 Gy), 3 fractions of 8 Gy (total: 24 Gy), 4 fractions of 8 Gy (total: 32 Gy), 5 fractions of 8 Gy (total: 40 Gy), 1 fraction of 9 Gy (total: 9 Gy), 2 fractions of 9 Gy (total: 18 Gy), 3 fractions of 9 Gy (total: 27 Gy), 4 fractions of 9 Gy (total: 36 Gy), 5 fractions of 9 Gy (total: 45 Gy), 1 fraction of 10 Gy (total: 10 Gy), 2 fractions of 10 Gy (total: 20 Gy), 3 fractions of 10 Gy (total: 30 Gy), 4 fractions of 10 Gy (total: 40 Gy), 1 fraction of 15 Gy (total: 15 Gy), 2 fractions of 15 Gy (total: 30 Gy), 3 fractions of 15 Gy (total: 45 Gy), 4 fractions of 15 Gy (total: 60 Gy), 1 fraction of 20 Gy (total: 20 Gy), 2 fractions of 20 Gy (total: 40 Gy), 3 fractions of 20 Gy (total: 60 Gy), 1 fraction of 25 Gy (total: 25 Gy), 2 fractions of 25 Gy (total: 50 Gy), 3 fractions of 25 Gy (total: 75 Gy), 1 fraction of 30 Gy (total: 30 Gy), and 2 fractions of 30 Gy (total: 60 Gy).

In a particularly preferred aspect, the subject is a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, a subject suffering from metastatic cancer for whom radiotherapy has been abandoned, or a subject suffering from a cancer which is not treated by radiotherapy, and the fractionated radiotherapy is selected from 1 fraction of 6 Gy (total: 6 Gy), 2 fractions of 6 Gy (total: 12 Gy), 3 fractions of 6 Gy (total: 18 Gy), 4 fractions of 6 Gy (total: 24 Gy), 5 fractions of 6 Gy (total: 30 Gy), 1 fraction of 7 Gy (total: 7 Gy), 2 fractions of 7 Gy (total: 14 Gy), 3 fractions of 7 Gy (total: 21 Gy), 4 fractions of 7 Gy (total: 28 Gy), 1 fraction of 8 Gy (total: 8 Gy), 2 fractions of 8 Gy (total: 16 Gy), 3 fractions of 8 Gy (total: 24 Gy), 4 fractions of 8 Gy (total: 32 Gy), 1 fraction of 9 Gy (total: 9 Gy), 2 fractions of 9 Gy (total: 18 Gy), 3 fractions of 9 Gy (total: 27 Gy), 1 fraction of 10 Gy (total: 10 Gy), 2 fractions of 10 Gy (total: 20 Gy), 3 fractions of 10 Gy (total: 30 Gy), 1 fraction of 15 Gy (total: 15 Gy), 2 fractions of 15 Gy (total: 30 Gy), 1 fraction of 20 Gy (total:

20 Gy), 2 fractions of 20 Gy (total: 40 Gy), 1 fraction of 25 Gy (total: 25 Gy) and 1 fraction of 30 Gy (total: 30 Gy).

### *Nanoparticle*

5

The nanoparticle used in the context of the invention advantageously consists in a material having a density of at least 7 g/cm<sup>3</sup> and an atomic number (Z) of at least 25. The nanoparticle or aggregate of nanoparticles is covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid.

10

In the spirit of the invention, the term “nanoparticle” refers to a product, in particular a synthetic product, with a size in the nanometer range, typically between 1 nm and 500 nm.

The term “aggregate of nanoparticles” refers to an assemblage of nanoparticles strongly, typically covalently, bound to each other.

15

Transmission electron microscopy (TEM) can be used to measure the size of the nanoparticle. As well, dynamic light scattering (DLS) can be used to measure the hydrodynamic diameter of nanoparticles in solution. These two methods may further be used one after each other to compare size measures and confirm said size. A preferred method is DLS (Ref. International Standard ISO22412 Particle Size Analysis- Dynamic Light Scattering, International Organisation for Standardisation (ISO) 2008). The largest dimension of a nanoparticle as herein defined is typically between about 4 nm and about 250 nm, preferably between about 4 nm or 10 nm and about 100 nm or about 200 nm, even more preferably between about 20 nm and about 150 nm.

20

25

As the shape of the particle can influence its “biocompatibility”, particle having a quite homogeneous shape is preferred. For pharmacokinetic reasons, nanoparticles being essentially spherical, round or ovoid in shape are thus preferred. Such a shape also favors the nanoparticle interaction with or uptake by cells. Spherical or round shape is particularly preferred.

Typically, the largest dimension is the diameter of a nanoparticle of round or spherical shape, or the longest length of a nanoparticle of ovoid or oval shape.

30

The inorganic material of the nanoparticle present in the composition preferably has a theoretical (bulk) density of at least 7 and may be selected from any material exhibiting this property and identified in the table from Physical Constants of Inorganic Compounds appearing on page 4-43 in Handbook of Chemistry and Physics (David R. Lide Editor-In-Chief, 88<sup>th</sup> Edition 2007-2008).

35

The inorganic material constituting the nanoparticle is preferably a material having an effective atomic number ( $Z_{\text{eff}}$ ) of at least 25, preferably at least 40 or 41, more preferably at least 50 or 51, more preferably at least 60, 61, 62 or even 63.

Effective atomic number is a term that is similar to atomic number but is used for compounds (e.g. water) and mixtures of different materials (such as tissue and bone) rather than for atoms. Effective atomic number calculates the average atomic number for a compound or mixture of materials. It is abbreviated  $Z_{\text{eff}}$ .

- 5 The effective atomic number is calculated by taking the fractional proportion of each atom in the compound and multiplying that by the atomic number of the atom. The formula for the effective atomic number,  $Z_{\text{eff}}$ , is as follows:

$$Z_{\text{eff}} = \sqrt[2.94]{f_1 \times (Z_1)^{2.94} + f_2 \times (Z_2)^{2.94} + f_3 \times (Z_3)^{2.94} + \dots}$$

where

- 10  $f_n$  is the fraction of the total number of electrons associated with each element, and  
 $Z_n$  is the atomic number of each element.

The atomic number (also known as the proton number) is the number of protons found in the nucleus of an atom. It is traditionally represented by the symbol  $Z$ . The atomic number uniquely identifies a chemical element. In an atom of neutral charge, atomic number is equal to the number of electrons.

- 15 An example is that of water ( $\text{H}_2\text{O}$ ) which is made up of two hydrogen atoms ( $Z=1$ ) and one oxygen atom ( $Z=8$ ). The total number of electrons is  $1+1+8 = 10$ . The fraction of electrons corresponding to the two hydrogens is  $2/10$  and the fraction of electrons corresponding to the unique oxygen is  $(8/10)$ .  $Z_{\text{eff}}$  of water is therefore:

$$Z_{\text{eff}} = \sqrt[2.94]{0.2 \times 1^{2.94} + 0.8 \times 8^{2.94}} = 7.42$$

- 20  $Z_{\text{eff}}$  participate to the incoming radiations absorption capacity of nanoparticles.

The inorganic material constituting the nanoparticle is typically selected from an oxide, a metal, a sulfide and any mixture thereof.

- When the inorganic material constituting the nanoparticle is an oxide, this oxide is advantageously  
 25 *selected from* Cerium (IV) oxide ( $\text{CeO}_2$ ), Neodymium (III) oxide ( $\text{Nd}_2\text{O}_3$ ), Samarium (III) oxide ( $\text{Sm}_2\text{O}_3$ ), Europium (III) oxide ( $\text{Eu}_2\text{O}_3$ ), Gadolinium (III) oxide ( $\text{Gd}_2\text{O}_3$ ), Terbium (III) oxide ( $\text{Tb}_2\text{O}_3$ ), Dysprosium (III) oxide ( $\text{Dy}_2\text{O}_3$ ), Holmium oxide ( $\text{Ho}_2\text{O}_3$ ), Erbium oxide ( $\text{Er}_2\text{O}_3$ ), Thulium (III) oxide ( $\text{Tm}_2\text{O}_3$ ), Ytterbium oxide ( $\text{Yb}_2\text{O}_3$ ), Lutetium oxide ( $\text{Lu}_2\text{O}_3$ ), Hafnium (IV) oxide ( $\text{HfO}_2$ ), Tantalum (V) oxide ( $\text{Ta}_2\text{O}_5$ ), Rhenium (IV) oxide ( $\text{ReO}_2$ ), Bismuth (III) ( $\text{Bi}_2\text{O}_3$ ). In the context of the present  
 30 invention, a mixture of inorganic oxides can also be used to prepare the nanoparticle of the invention.

- When the inorganic material constituting the nanoparticle is *a metal*, *this metal is advantageously*  
 selected from gold (Au), silver (Ag), platinum (Pt), palladium (Pd), tin (Sn), tantalum (Ta), ytterbium (Yb), zirconium (Zr), hafnium (Hf), terbium (Tb), thulium (Tm), cerium (Ce), dysprosium (Dy),  
 35 erbium (Er), europium (Eu), holmium (Ho), iron (Fe), lanthanum (La), neodymium (Nd), praseodymium (Pr), lutetium (Lu). In the context of the present invention, mixture of metals is also

possible. In the context of the present invention, a mixture of an inorganic oxide and of a metal can also be used to prepare the nanoparticle of the invention.

When the inorganic material constituting the nanoparticle is a sulfide, this sulfide is preferably silver sulfide ( $\text{Ag}_2\text{S}$ ).

In a preferred embodiment, the nanoparticle used in the context of the present invention to prepare a composition of interest can be coated with a biocompatible material selected from an agent exhibiting stealth property. Indeed, when the nanoparticles of the present invention are administered to a subject via the intravenous (IV) route, a biocompatible coating with a material selected from an agent exhibiting stealth property is particularly advantageous to optimize the biodistribution of the nanoparticles. Said coating is responsible for the so called “stealth property” of the nanoparticle.

Agent exhibiting stealth properties may be an agent displaying a steric group. Such a group may be selected for example from polyethylene glycol (PEG); polyethylenoxide; polyvinylalcohol; polyacrylate; polyacrylamide (poly(N-isopropylacrylamide)); polycarbamide; a biopolymer; a polysaccharide such as dextran, xylan and cellulose; collagen; a switterionic compound such as polysulfobetain; etc.

In another preferred embodiment, the nanoparticles can be coated with a biocompatible material selected from an agent allowing interaction with a biological target. Such an agent can typically bring a positive or a negative charge on the nanoparticle’s surface. This charge can be determined by zeta potential measurements, typically performed on nanoparticles suspensions the concentration of which vary between 0.2 and 10 g/L, the nanoparticles being suspended in an aqueous medium with a pH comprised between 6 and 8.

An agent forming a positive charge on the nanoparticle surface can be for example aminopropyltriethoxysilane or polylysine. An agent forming a negative charge on the nanoparticle surface can be for example a phosphate (for example a polyphosphate, a metaphosphate, a pyrophosphate, etc.), a carboxylate (for example citrate or dicarboxylic acid, in particular succinic acid) or a sulphate.

A full biocompatible coating of the nanoparticle or aggregate may be advantageous, in particular in the intravenous (IV) context, in order to avoid interaction of the particle surface with any recognition element (macrophage, opsonins, etc.). The “full coating” implies the presence of a very high compactness of biocompatible molecules able to create at least a complete monolayer on the surface of the particle.

The biocompatible coating allows in particular the nanoparticle stability in a fluid, such as a physiological fluid (blood, plasma, serum, etc.) or any isotonic media or physiologic medium required for a pharmaceutical administration.

Stability may be confirmed by dry extract quantification using a drying oven and measured on a nanoparticle suspension prior and after filtration, typically on a 0.22 or 0.45  $\mu\text{m}$  filter.

Advantageously, the coating preserves the integrity of the particle *in vivo*, ensures or improves the biocompatibility thereof, and facilitates an optional functionalization thereof (for example with spacer molecules, biocompatible polymers, targeting agents, proteins, etc.).

A particular nanoparticle according to the present invention can further comprise a targeting agent allowing its interaction with a recognition element present on the target cell. Such a targeting agent typically acts once the nanoparticles are accumulated on the target site. The targeting agent can be any biological or chemical structure displaying affinity for molecules present in the human or animal body. For instance it can be a peptide, oligopeptide or polypeptide, a protein, a nucleic acid (DNA, RNA, siRNA, tRNA, miRNA, etc.), a hormone, a vitamin, an enzyme, the ligand of a molecule expressed by a pathological cell, in particular the ligand of a tumor antigen, hormone receptor, cytokine receptor or growth factor receptor. Said targeting agents can be selected for example in the group consisting in LHRH, EGF, a folate, anti-B-FN antibody, E-selectin/P-selectin, anti-IL-2R  $\alpha$  antibody, GHRH, etc.

### *Composition*

Inventors also herein describe a therapeutic composition, typically a vaccine composition, for use in a subject suffering from cancer as herein defined, preferably from a metastatic cancer or from a liquid cancer, in the context of radiotherapy, typically of a fractionated radiotherapy as herein defined, wherein the composition comprises (i) a nanoparticle or aggregate of nanoparticles, each nanoparticle consisting in a material having a density of at least 7  $\text{g}/\text{cm}^3$  and an atomic number (Z) of at least 25, and each nanoparticle or aggregate of nanoparticles being covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid, preferably together with (ii) a pharmaceutically acceptable carrier or vehicle.

In a particular embodiment, a vaccine composition is herein described which comprises a nanoparticle and/or aggregate of nanoparticles for use for treating cancer in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom (curative) radiotherapy has been abandoned, in a subject suffering from a cancer which is not treated by radiotherapy, or in a subject suffering from a liquid cancer, wherein the treatment comprises exposing the subject to a fractionated radiotherapy comprising at least one irradiation step wherein the ionizing radiations dose ranges from 1.8 to 30 Gray (Gy), preferably 1.8 to 20 Gray (Gy), and wherein each nanoparticle consists in a material having a density of at least 7  $\text{g}/\text{cm}^3$  and an atomic number (Z) of at least 25 and each nanoparticle or aggregate of nanoparticles is covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid. The



composition may comprise in addition to the nanoparticle and/or aggregate of nanoparticles a pharmaceutically acceptable carrier or vehicle.

The pharmaceutically acceptable carrier or vehicle can be any classical support for the skilled person, such as for example a saline, isotonic, sterile, buffered solution, a non-aqueous vehicle solution and the like. A typical carrier is a isotonic media or physiological media comprising NaCl, PBS and/or Glucose. The carrier can for example comprise glucose (5%) or dextrose (5%) and/or NaCl (0.9 %).

The composition can also comprise stabilizers, sweeteners, surfactants, polymers and the like.

The composition can be in the form of a solid, liquid (particles in suspension), aerosol, gel, paste, and the like. Preferred compositions are in a liquid or a gel form. Particularly preferred compositions are in liquid form.

It can be formulated for example as ampoule, syringe, aerosol, bottle, vial, tablet, capsule, by using techniques of pharmaceutical formulation known by the skill person.

Generally, the composition, in liquid or gel form, comprise between about 0.05g/L and about 450g/L of nanoparticles or aggregates of nanoparticles, between about 0.05 g/L and about 250 g/L of nanoparticles, preferably at least about 10 g/L, 11 g/L, 12 g/L, 13 g/L, 14 g/L, 15 g/L, 16 g/L, 17 g/L, 18 g/L, 19 g/L, 20 g/L, 21 g/L, 22 g/L, 23 g/L, 24 g/L, 25 g/L, 26 g/L, 27 g/L, 28 g/L, 29 g/L, 30 g/L, 31 g/L, 32 g/L, 33 g/L, 34 g/L, 35 g/L, 36 g/L, 37 g/L, 38 g/L, 39 g/L, 40 g/L, 41 g/L, 42 g/L, 43 g/L, 44 g/L, 45 g/L, 46 g/L, 47 g/L, 48 g/L, 49 g/L, 50 g/L, 51 g/L, 52 g/L, 53 g/L, 54 g/L, 55 g/L, 56 g/L, 57 g/L, 58 g/L, 59 g/L, 60 g/L, 61 g/L, 62 g/L, 63 g/L, 64 g/L, 65 g/L, 66 g/L, 67 g/L, 68 g/L, 69 g/L, 70 g/L, 71 g/L, 72 g/L, 73 g/L, 74 g/L, 75 g/L, 76 g/L, 77 g/L, 78 g/L, 79 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, 100 g/L, 150 g/L, 200 g/L, 250 g/L, 300 g/L, 350 g/L, or 400 g/L of nanoparticles.

The concentration of nanoparticles in the composition can be measured by dry extract. A dry extract is ideally measured following a drying step of the suspension comprising the nanoparticles in a drying oven.

In a particular embodiment, the composition further comprises at least one immunotherapeutic agent and optionally an additional therapeutic agent for treating cancer.

The terms “immunotherapeutic agent” herein designates typically any molecule, drug, cell or cell-based vaccine, oncolytic virus, DNA-based vaccine, peptide-based vaccine, toll-like receptor agonist, vesicle derived from a cell as well as any combination thereof capable of boosting the immune system of a subject and recognized as such by the skilled person.

The molecule or drug can for example be selected from a monoclonal antibody, a cytokine, and a combination thereof.

The drug can typically be an indoleamine 2,3-dioxygenase (IDO) inhibitor such as 1-methyl-D-tryptophan

- 5 In a preferred embodiment, the monoclonal antibody inhibits the CTLA-4 molecule or the interaction between PD-1 and its ligands. The monoclonal antibody is advantageously selected from anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2. The monoclonal antibody can for example be selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab and lambrolizumab.

- 10 In another preferred embodiment, the monoclonal antibody enhances CD27 signaling, CD137 signaling, OX-40 signaling, GITR signaling and/or MHCII signaling, and/or activate CD40. The monoclonal antibody can for example be selected from dacetuzumab, Lucatumumab, and urelumab.

In a further embodiment, the monoclonal antibody inhibits TGF- $\beta$  signaling or KIR signaling. The monoclonal antibody can for example be selected from fresolimumab and lirilumab.

- 15 The cytokine can be advantageously selected from the granulocyte-macrophage colony stimulating factor (GM-CSF), a fms-related tyrosine kinase 3 ligand (FLT3L), IFN- $\alpha$ , IFN- $\alpha$ 2b, IFN $\gamma$ , IL2, IL-7, IL-10 and IL-15.

In another preferred embodiment, the immunotherapeutic agent is an immunocytokine, for example the immunocytokine L19-IL2 (Nicolle H. Rekers Radiotherapy and Oncology 2015).

- 20 The cell as used as an immunotherapeutic agent is typically an immune cell presenting or sensitized to a tumor antigen, preferably a tumor antigen specific of the cancer to be treated, such as a dendritic cell or a T-cell; a cell secreting an immunogenic molecule; or a dead tumor cell or a dying tumor cell undergoing an immunogenic cell death, i.e. a cell expressing CRT and/or producing HMGB1 and/or producing ATP in a ICD typical amount, for example a dying or dead-tumor cell which has been exposed to radiotherapy. The cell can be an autologous cell or an allogeneic cell. The cell is preferably  
25 an autologous cell isolated from the subject to be treated. The dead- or dying-tumor cell can be a tumor mature cell or a tumor stem cell.

The toll-like receptor agonist is advantageously selected from a TLR 2/4 agonist, a TRL 7 agonist, a TRL 7/8 agonist and a TRL 9 agonist. The toll-like receptor agonist can for example be selected from imiquimod, bacillus Calmette-Guérin and monophosphoryl lipid A.

- 30 A preferred combination of immunotherapeutic agents can be for example selected from a cytokine, a monoclonal antibody, a Toll-like receptor agonist and a peptide-based vaccine.

- 35 The terms “therapeutic agent for treating cancer” herein typically designates an agent used in a conventional treatment of cancer such a biological compound, a small molecule targeted therapeutic, or a cytotoxic compound.

A biological compound is for instance an antibody, preferably a monoclonal antibody (“mAb”) such as Alemtuzumab, Brentuximab Vedotin, Catumaxoma, Denosumab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Pertuzumab, Ofatumumab, bevacizumab, rituximab, trastuzumab, cetuximab, panatimumab or tositumomab.

- 5 A small molecule targeted therapeutic generally inhibits enzymatic domains on mutated, overexpressed, or otherwise critical protein (potential target in the context of cancer treatment) within the malignant cells. Some therapeutic agents include those that target cell division (for example a aurora-kinase inhibitor or a cyclin-dependent-kinase inhibitor), as well as other biological mechanisms such as protein turnover and chromatin modification (for example a histone-deacetylase inhibitor).
- 10 Small molecules targeted therapeutics can for example be selected from imatinib, rapamycin, gefitinib, erlotinib, sorafenib, sunitinib, nilotinib, dasatinib, lapatinib, bortezomib and atorvastatin, etc. A cytotoxic compound is for example a DNA-modifying agent such as an anthracyclin (such as dexamethasone, daunorubicin, idarubicin or methotrexate) or an antimitotic agent (spindle poison such as vincristine or vinblastine); a taxane such as docetaxel, larotaxel, cabazitaxel, paclitaxel (PG-
- 15 paclitaxel and DHA-paclitaxel), ortataxel, tesetaxel or taxoprexin; gemcitabine; etoposide; mitomycin C; an alkylating agent (for example melphalan or temozolomide); a platin based component such as oxaliplatin or carboplatin; a TLR (Toll-like receptor)-3 ligand; and a prodrug. The prodrug (for instance capecitabine or irinotecan) is metabolized in its active form *in vivo* to produce its expected therapeutic effect.
- 20 Other typical cytotoxic compounds are typically selected from chemotherapeutic agents as herein described or as known by the skilled oncologist.

The herein described vaccine composition comprising at least one immunotherapeutic agent, possibly in combination with a least one therapeutic agent for treating cancer, can be administered to the

25 subject to be treated either simultaneously or separately from the nanoparticles or aggregates of nanoparticles as herein described.

### *Kit*

- 30 Inventors also herein describe a vaccine kit comprising (i) a nanoparticle or aggregate of nanoparticles consisting in a material having a density of at least  $7 \text{ g/cm}^3$  and an atomic number ( $Z$ ) of at least 25, each nanoparticle or aggregate of nanoparticles being covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid, or a vaccine composition as herein described, preferably together with (ii) at least one immunotherapeutic agent and/or therapeutic
- 35 agent for treating cancer as herein described, and optionally (iii) a leaflet providing instructions to perform the vaccination in the context of radiotherapy.

*Protocol*

The nanoparticles or aggregates of nanoparticles as herein described or the composition comprising such nanoparticles or aggregates of nanoparticles are advantageously contacted with the cancer cells before radiotherapy, typically the fractionated radiotherapy, is applied. The contact between nanoparticles and cancer cells can be performed *ex vivo* following biopsy or blood sampling, or *in vivo* through administration to the subject to be treated either systemically or directly into the tumor, tumor bed (after tumor resection by surgery) or tumor metastase(s).

When administered *in vivo*, the nanoparticles of the invention can be administered to the subject using different possible routes such as local [intra-tumoral (IT), intra-arterial (IA)], subcutaneous, intra venous (IV), intra-dermic, airways (inhalation), intra peritoneal, intra muscular, intra-articular, intra-theecal, intra-ocular or oral route (*per os*), preferably using IT, IV or IA.

Repeated injections or administrations of nanoparticles can be performed, when appropriate.

In a particular embodiment, the nanoparticle or aggregate of nanoparticles is advantageously administered to the subject to be treated together with at least one immunotherapeutic agent. The nanoparticle or aggregate of nanoparticles, or the composition comprising such nanoparticle or aggregate of nanoparticles, and the at least one immunotherapeutic agent can be administered to the subject either simultaneously or separately.

In a particular embodiment, when the cancer is a metastatic cancer and/or is a cancer which is not (conventionally) treated by radiotherapy, the at least one irradiation step is typically applied *in vivo* on one, at most two, tumor sites of the metastatic cancer comprising the nanoparticles or aggregates of nanoparticles. Thanks to the nanoparticles or aggregates of nanoparticles used as a vaccine the anti-cancer effect of radiotherapy can be observed outside of the irradiated area or site due to the efficient mobilization of the subject's immune system.

Typically, inventors herein demonstrate that a marked increase of HMGB1 released from dying cancer cell is observed with the nanoparticles or aggregates of nanoparticles of the invention exposed to ionizing radiations when compared to radiation alone in both radiosensitive HCT 116 (human colorectal cancer cell line) and radioresistants 42 MG BA (human glioblastoma cell line) and PANC-1 (human pancreas cancer cell line), using a single dose of radiations. Moreover, a marked increase of ATP secretion from dying cancer cell is observed with the nanoparticles or aggregates of nanoparticles of the invention exposed to ionizing radiations when compared to radiation alone in HCT 116 cancer cell line.

These DAMPs are an indication of the immunogenic cell death of cancer cells, and the nanoparticles or aggregates of nanoparticles of the present invention when exposed to radiations therapy are able to amplify their secretion and release.

In addition, results of the vaccination assay performed in immunocompetent mice show the ability of the nanoparticles or aggregates of nanoparticles of the invention to efficiently mobilize the immune system of the animals, preventing the apparition of tumors when animals are first vaccinated with irradiated cancer cells and then challenged 7 days after with viable cancer cells: 66% of the animals are tumor free in the group vaccinated with cancer cell treated with the nanoparticles and 6 Gy whereas only 33% of the animal are tumor free when vaccinated with cancer cells irradiated with 6 Gy alone.

These data strongly support the use of these nanoparticles or aggregates of nanoparticles as a vaccine to generate the anti-cancer effect of radiotherapy outside of the irradiated area or site due to the efficient mobilization of the subject's immune system.

In a preferred embodiment, the nanoparticle or nanoparticles' aggregate of the invention, or the composition of the invention comprising such a nanoparticle or nanoparticles' aggregate allows the alteration or destruction of metastatic cancer cells present in lung (e.g. when the primary cancer is for example a sarcoma, bladder cancer, breast cancer, colon cancer, kidney cancer or prostate cancer), liver (e.g. when the primary cancer is for example a gastrointestinal cancer, a breast cancer, a colon cancer, lung cancer or skin cancer), bone (e.g. when the primary cancer is for example a breast cancer, a prostate cancer or a lung cancer) and/or brain (e.g. when the primary cancer is for example a lung cancer, a renal cancer, a melanoma or a breast cancer).

In another particular embodiment, the at least one irradiation step is applied *ex vivo* on a cancer sample of the subject comprising the nanoparticles or aggregates of nanoparticles, and the *ex vivo* lethally irradiated cancer cells together with at least part of the associated cell supernatant from the cancer sample are at least partly readministered to the subject before any optional subsequent *in vivo* treatment of cancer in said subject.

Cell supernatant from the irradiated cancer sample typically comprises immunogenic molecules such as HMGB1, ATP, various chaperones of the heat shock protein (HSP) family, notably the heat shock 70 kDa protein (HSP70) and the heat shock 90 kDa protein (HSP90), immunostimulatory cytokines like interferon  $\alpha$  (IFN $\alpha$ ), sphingomyelin metabolites, product from the breakdown of the extracellular matrix, etc. In the context of the present invention, the enhanced release of immunogenic molecules in the cell supernatant from the irradiated cancer sample comprising the nanoparticles or aggregate of nanoparticles, when compared to irradiated cancer sample with absence of nanoparticles or aggregate of nanoparticles (see example 4), is capable of further amplifying the anti-cancer treatment.

Readministration into the subject to be treated is typically performed through subcutaneous or intradermal injection.

When the cancer is a liquid cancer, the at least one irradiation step is typically applied *ex vivo* on a liquid cancer sample of the subject comprising the nanoparticles or aggregates of nanoparticles, and the irradiated liquid cancer sample is at least partly readministered to the subject before any optional subsequent *in vivo* treatment of cancer in said subject.

Readministration into the subject to be treated can be performed through subcutaneous or intradermal injection. It can also be performed through intraarterial (IA), intravenous (IV) or intraperitoneal (IP) injection.

The liquid cancer sample is typically a blood sample or the whole blood volume of the subject to be treated. When the whole blood volume of the subject is to be irradiated, irradiation can be performed *ex vivo* during an extra corporeal circulation protocol, the irradiated whole blood volume being completely readministered to the subject.

Of interest, Y. Suzuki et al. (2012) reported that tumor antigen-specific T-cell responses were observed in 38% of patients with esophageal squamous cell carcinoma (ESCC) after chemoradiotherapy and that these responses were coexisting with an elevated HMGB1 concentration in the serum of these patients. HMGB1 within tumor microenvironment was significantly upregulated in patients with ESCC with preoperative chemoradiotherapy, but not in those without chemoradiotherapy, and the degree of HMGB1 positively correlated with patient survival.

In a preferred embodiment, the *ex vivo* lethally irradiated cancer cells or the irradiated liquid cancer sample is at least partly readministered to the subject together with at least one additional immunotherapeutic agent and/or therapeutic agent for treating cancer as herein described.

The *ex vivo* lethally irradiated cancer cells or the irradiated liquid cancer sample and the least one additional immunotherapeutic agent and/or the at least therapeutic agent for treating cancer can be administered to the subject either simultaneously or separately.

Other aspects and advantages of the invention will become apparent in the following examples, which are given for purposes of illustration and not by way of limitation.

## EXPERIMENTAL SECTION

### **EXAMPLE 1: Functionalized hafnium oxide (HfO<sub>2</sub>) nanoparticles synthesis and characterization**

5 A Tetramethylammonium hydroxide (TMAOH) solution is added to 40 g of HfCl<sub>4</sub> solution. Addition of TMAOH solution is performed until the pH of the final suspension reaches a pH comprised between 7 and 13. A white precipitate is obtained.

The precipitate is further transferred in an autoclave and heated at a temperature comprised between 120 °C and 300 °C to perform crystallization. After cooling, the suspension is washed with de-ionized  
10 water.

A peptization step, is performed in order to get a stable suspension of nanoparticles or nanoparticle aggregates.

Suspension of Sodium hexametaphosphate is then added to the peptized solution (the amount of sodium hexametaphosphate added being below LD50/5) and the pH of the suspension is adjusted to a  
15 pH comprised between 6.5 and 7.5.

For *in vitro* experiments a sterilization step is performed at this stage for example using a 0.22 µm filter.

For *in vivo* experiments, a formulation step using glucose 5% can be performed before or after the sterilization step.

20 The following table presents the main characteristics of the suspension of biocompatible nanoparticles or nanoparticle aggregates thus obtained.

Density	Morphology	Specific surface area (SS) in m <sup>2</sup> /g	Mean hydrodynamic diameter (Φ) in nm
8.3	Spherical in shape	20 < SS < 60	15 < Φ < 200

25 **EXAMPLE 2: Gold nanoparticles synthesis and physico-chemical characterization of gold nanoparticles of different sizes.**

Gold nanoparticles are obtained by reduction of gold chloride with sodium citrate in aqueous solution. Protocol was adapted from G. Frens Nature Physical Science 241 (1973) 21.

In a typical experiment, HAuCl<sub>4</sub> solution is heated to boiling. Subsequently, sodium citrate solution is  
30 added. The resulting solution is maintained under boiling for an additional period of 5 minutes.

The nanoparticle size is adjusted from 15 up to 105 nm by carefully modifying the citrate versus gold precursor ratio (cf. Table 1).

The as prepared gold nanoparticles suspensions are then concentrated using an ultrafiltration device (Amicon stirred cell model 8400 from Millipore) with a 30 kDa cellulose membrane.

The resulting suspensions are ultimately filtered through a 0.22  $\mu\text{m}$  cutoff membrane filter (PES membrane from Millipore) under laminar hood and stored at 4°C.

- 5 Particle size is determined using Transmission Electronic Microscopy (TEM) by counting more than 200 particles, taking the longest nanoparticle dimension for size measurement.

**Table 1:**

Samples	Particle size (nm)	Synthesis	
		Citrate	HAuCl <sub>4</sub>
Gold-15	15±2 (1 $\sigma$ )	20 mL 30 mM	500 mL 0.25 mM
Gold-30	32±10 (1 $\sigma$ )	7.5 mL 40 mM	500 mL 0.25 mM
Gold-60	60±10 (1 $\sigma$ )	2 mL 85 mM	500 mL 0.25 mM
Gold-80	80± 10(1 $\sigma$ )	1.2 mL 43 mM	200 mL 0.30 mM
Gold-105	105±25 (1 $\sigma$ )	1.2 mL 39 mM	200 mL 0.33 mM

- 10 **EXAMPLE 3: Nanoparticles suspension comprising a gold material at least partially covered with hafnium oxide material.**

A Tetramethylammonium hydroxide (TMAOH) solution is added to hafnium chloride (HfCl<sub>4</sub>) solution. Addition of TMAOH solution is performed until the pH of the final suspension reaches a pH  
15 comprised between 7 and 13. A white precipitate is obtained.

Gold particles suspension from example 2 is slowly added to the white precipitate under vigorous mixing.

The resulting precipitate is further transferred in an autoclave and heated at a temperature comprised between 100 °C and 300 °C. After cooling, the suspension is washed with water.

- 20 A peptization step is performed in order to get a stable suspension of nanoparticles comprising gold material at least partly embedded in hafnium oxide material.  
Suspension of sodium hexametaphosphate is then added to the peptized solution and the pH of the suspension is adjusted to a pH comprised between 6 and 8.

- 25 **EXAMPLE 4: HMGB1 release from dying cancer cell.**

HMGB1 release from dying cancer cell was studied using the 42 MG BA human glioblastoma cell line. The cell line 42-MG-BA was purchased from the Deutsche Sammlung von Mikroorganismen



und Zellkulturen GmbH German Collection of Microorganism and Cell Cultures (Braunschweig, Germany).

Cells were dispersed in T25 flasks within the range of  $1.5 \times 10^6$  to  $2 \times 10^6$  cells/flasks. When cells were attached to the plate, HfO<sub>2</sub> nanoparticle suspension from example 1 at a concentration equal to 400  $\mu$ M was added overnight (12 h-15 h) to the cells before delivering the radiation dose. The cells were cultured with antibiotics (Penistrepto).

A single X-ray irradiation dose of 5 Gy or 10 Gy was delivered at a dose rate of 1.26 Gy min<sup>-1</sup> using X-Ray generator (200 kV, 15 mA, 0.2 mm Copper filtration).

The cells were cultured for 96 hours at 37°C under a 5% CO<sub>2</sub> humidified atmosphere. After 96 hours, the cell supernatant was collected and concentrated using centricon.

HMGB1 was quantified in the concentrated cell supernatants using enzyme-linked immunosorbent assay (ELISA) kit specific for human HMGB1.

Figure 1 presents HMGB1 released from dying cancer cells. The HMGB1 released in the concentrated cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticle suspension from example 1 and exposed or not to radiotherapy (5 Gy delivered in 1 fraction) is reported as fold-change in comparison to untreated control (i.e. the 42 MG BA cell line without irradiation).

Figure 2 presents HMGB1 released from dying cancer cells. The HMGB1 released in the concentrated cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticle suspension from example 1 and exposed or not to radiotherapy (10 Gy delivered in 1 fraction) is reported as fold-change in comparison to untreated control (i.e. the 42 MG BA cell line without irradiation).

### Conclusion

A marked increase of HMGB1 released from dying cancer cells is observed in the concentrated cell supernatant from cells treated with hafnium oxide nanoparticles from example 1 when exposed to a single irradiation dose of 5 Gy or 10 Gy, when compared to radiation alone. These results support the rational for using these nanoparticles or aggregates of nanoparticles as a therapeutic vaccine in the context of radiotherapy.

### **EXAMPLE 5: HMGB1 release from dying cancer cells across cell lines**

HMGB1 release from dying cancer cell was studied using the HCT 116 human colorectal cell line, the 42 MG BA human glioblastoma cell line and the PANC-1 human pancreas cell line. The cell lines were purchased from the “American Type Culture Collection” (ATCC) (HCT 116, Catalog No. CCL-247 and PANC-1, Catalog No. CRL-1469) or from the “Deutsche Sammlung von Mikroorganismen und Zellkulturen” (DSMZ) (42 MG BA, Catalog No. ACC 431).

Cells were dispersed in T25 flasks at  $1 \cdot 10^6$  cells/flask. When cells were attached to the plate, HfO<sub>2</sub> nanoparticles suspension from example 1 at a concentration equal to 800  $\mu$ M (for HCT 116) or

400 $\mu$ M, (for PANC-1 and 42 MG) was added overnight (12h-15h) to the cells before delivering the radiation dose. The cells were cultured with antibiotics (medium with 1% Penicillin-Streptomycin). X-ray irradiation doses were delivered at a dose rate of 1 Gy.min<sup>-1</sup> using X-ray generator (320kV, X-RAD 320). The radiation dose for each cell line is given in table 3.

5

Table 3: irradiation doses for each cell line

Cell line	HCT 116	42 MG BA	PANC-1
Irradiation doses	4 Gy 6 Gy	10 Gy 15 Gy	8 Gy

HCT 116 cell line: cells were cultured 72 hours at 37°C under a 5% CO<sub>2</sub> humidified atmosphere. After 72 hours, the cell supernatant was collected.

10 42 MG BA and PANC-1 cell lines: cells were cultured 96 hours at 37°C under a 5% CO<sub>2</sub> humidified atmosphere. After 96 hours, the cell supernatant was collected and concentrated using Centricon.

HMGB1 was quantified in the cell supernatants using enzyme-linked immunosorbent assay (ELISA) kit specific for human HMGB1 (such as “HMGB1 ELISA Kit” from IBL international, Catalog No. ST51011).

15

Figure 3 presents HMGB1 released from dying cancer cells. The HMGB1 released in the cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticles suspension from example 1 and exposed or not to radiotherapy (delivered in 1 fraction) are reported as fold-change in comparison to untreated control.

20 Figure 3 A represents HMGB1 released from dying HCT 116 cancer cells. Irradiation doses were equal to 4 Gy and 6 Gy. Experiments is the mean of 2 independent experiments performed in triplicate and pooled.

Figure 3 B represents HMGB1 released from dying 42 MG BA cancer cells. Irradiation doses were equal to 10 Gy and 15 Gy. Experiments is the mean of 2 independent experiments performed in triplicate and pooled.

25

Figure 3 C represents HMGB1 released from dying PANC-1 cancer cells. Irradiation dose was equal to 8 Gy. Experiments are the mean of 2 independent experiments performed in triplicate and pooled.

### Conclusion

30 A marked increase of HMGB1 released from dying cancer cells is observed in the supernatant from cells treated with hafnium oxide nanoparticles from example 1 when exposed to a single irradiation dose, when compared to radiation alone. These results support the rationale for using these nanoparticles and/or aggregates of nanoparticles as a therapeutic vaccine in the context of radiotherapy across a large variety of cancers.

**EXAMPLE 6: ATP secretion from dying cancer cells**

ATP secretion from dying cancer cell was studied using the HCT 116 human colorectal cancer cell line. The cell line HCT 116 was purchased from the “American Type Culture Collection” (ATCC) (HCT 116, Catalog No. CCL-247).

Cells were dispersed in T25 flasks at concentration equal to  $2 \times 10^6$  cells/flask. When cells were attached to the plate, HfO<sub>2</sub> nanoparticles from example 1 at a concentration equal to 800μM were added overnight (12h-15h) to cells before delivering the radiation dose. The cells were cultured with antibiotics (medium containing 1% Penicillin-Streptomycin).

A single X-ray irradiation dose of 6 Gy was delivered at a dose rate of 1 Gy.min<sup>-1</sup> using X-ray generator (320kV, X-RAD 320).

The cells were cultured for 9 hours at 37°C under a 5% CO<sub>2</sub> humidified atmosphere. After 9 hours, the cell supernatant was collected.

ATP secretion was quantified in the cell supernatants using a bioluminescence detection kit for ATP measurement (such as “ENLITEN® ATP Assay System” from Promega, Catalog. No. FF2000).

Figure 4 presents ATP secretion from HCT 116 dying cancer cells. The ATP secretion in the cell supernatant from cells treated or not with HfO<sub>2</sub> nanoparticle suspension from example 1 and exposed or not to radiotherapy (6 Gy delivered in 1 fraction) is reported as fold-change in comparison to untreated control (i.e. the HCT 116 cell line without irradiation). Experiment is the mean of 3 independent experiments performed in triplicate and pooled.

**Conclusion**

A marked increase of ATP secretion from dying cancer cells is observed in the supernatant from cells treated with hafnium oxide nanoparticles from example 1 when exposed to a single irradiation dose, when compared to radiation alone. These results support the rationale for using these nanoparticles and/or aggregates of nanoparticles as a therapeutic vaccine in the context of radiotherapy.

**EXAMPLE 7: vaccination assay**

As presented in the article entitled “Consensus guidelines for the detection of immunogenic cell death” (Oliver Kepp et al. OncoImmunology 2014), the gold-standard approach to evaluate the ability of a specific stimulus to cause true ICD relies on vaccination assays. In this setting, murine cancer cells of choice are exposed *in vitro* to an inducer of immunogenic cell death (ICD), and eventually injected subcutaneously (s.c.) into one flank (vaccination site) of immunocompetent syngeneic mice (ideally 5–10 per group). One week later, mice are challenged with living cancer cells of the same type, which are inoculated s.c. into the contralateral flank (challenge site). Tumor incidence and

growth are routinely monitored at both injection sites over a 1-2 months period. The development of neoplastic lesions at the vaccination site indicates that the stimulus under investigation is unable to cause cell death (under the tested conditions) to a degree that is compatible with the elicitation of adaptive immunity. Conversely, in the absence of tumors at the vaccination site, the ability of the stimulus under examination to promote true ICD inversely correlates with the number of neoplastic lesions developed at the challenge site.

Here the murine CT 26 colorectal cancer cells were chosen for the vaccination assay. The cell line was purchased from the "American Type Culture Collection" (ATCC) (CT26, Catalog No. CRL2638).

Cells were dispersed in T300 flasks at  $10 \times 10^6$  cells/flask. When cells were attached to the plate, HfO<sub>2</sub> nanoparticles suspension from example 1 at a concentration equal to 400 μM was added overnight (12h-15h) to the cells before delivering the radiation dose. The cells were cultured with antibiotics (medium with 1% Penicillin-Streptomycin).

X-ray irradiation doses were delivered at a dose rate of 1 Gy.min<sup>-1</sup> using X-ray generator (320kV, X-RAD 320). A single fraction of 6 Gy was delivered to the cells treated or not with HfO<sub>2</sub> NP from example 1.

The cells were cultured for 48 hours at 37°C under a 5% CO<sub>2</sub> humidified atmosphere. After 48 hours, the cells were collected, washed with PBS before trypsinization and  $1.10^6$  viable cells were injected subcutaneously in the left flank of immunocompetent Balb/c mice. For the control group, 100 μL of PBS was injected subcutaneously in the left flank of the mice.

Seven days later, mice were challenged with untreated living CT 26 cells:  $3.10^5$  cells were injected subcutaneously in the right flank of the mice (Figure 5). Tumor incidence and growth were monitored twice per week at both injection sites over 47 days (Figure 6).

### Conclusion

Forty-seven (47) days post vaccination, 66% of mice were tumor free in the group treated with HfO<sub>2</sub> NP from example 1 and 6 Gy irradiation versus 33% for mice treated with irradiation 6 Gy alone. A marked increase of tumor free mice is observed when vaccination is performed with cells treated with hafnium oxide nanoparticles from example 1 and exposed to a single irradiation dose, when compared to radiation alone. These results support the rationale for using these nanoparticles and/or aggregates of nanoparticles as a therapeutic vaccine in the context of radiotherapy.

These data demonstrate the ability of the nanoparticles or aggregates of nanoparticles of the invention when exposed to radiotherapy to establish an efficient mobilization of the subject's immune system when compared to radiotherapy alone.

Such efficient immune response, triggered by the use of the nanoparticles or aggregates of nanoparticles of the invention when exposed to radiotherapy, is of particular interest for selected patients populations, typically for subjects suffering from metastatic cancers and/or undergoing a palliative radiotherapy, for subjects suffering from metastatic cancers for whom radiotherapy has been

abandoned, for subjects suffering from a cancer which is not (conventionally) treated by radiotherapy, or for subjects suffering from liquid cancers.

## REFERENCES

- Dhara M. MacDermid et al. A rationale for the targeted treatment of oligometastases with radiotherapy. *Journal of Surgical Oncology* 2008. 98 202-206.
- 5 - Ralph R. Weichselbaum et al. Oligometastases revisited. *Nat. Rev. Clin. Oncol.* 2011. 8, 378-382.
- Sonam Sharma et al. Palliative radiotherapy: current status and future directions. *Seminars on Oncology* 2014. 41 (6) 751-763.
- Sandra Demaria and Silvia C. Formenti. Radiation as an immunological adjuvant: current evidence on dose and fractionation. *Frontiers in Oncology*. October 2012 Volume 2 Article 153 1-7.
- 10 - Oliver Kepp. Consensus guidelines for the detection of immunogenic cell death. *Oncoimmunology* 2014 3(9) e955691.
- Kobe Reynders et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. *Cancer Treatment Review* 2015 41(6), 503-510.
- Scott J. Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects. *Clinical Cancer Research*; 20(24) 2014 6258-6268.
- 15 - Theresa L. Whiteside et al. Emerging opportunities and challenges in cancer immunotherapy. *Clin Cancer Res* 2016. 22(8) 1845-1855.
- Nicolle H. Rekers et al. Combination of radiotherapy with the immunocytokine L19-IL2 : additive effect in a NK cell dependent tumour model. *Radiotherapy and Oncology* 2015, 116 438-442.
- 20 - Y. Suzuki et al. Immunogenic Tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC). *Cancer Res.* 2012.72(16) 3967-76.

## CLAIMS

1. A vaccine composition comprising a nanoparticle and/or aggregate of nanoparticles for use for  
5 treating cancer in a subject suffering from a metastatic cancer or from a liquid cancer, wherein the treatment comprises exposing the subject to a fractionated radiotherapy comprising at least one irradiation step wherein the ionizing radiations dose ranges from 1.8 to 20 Gray (Gy), and wherein each nanoparticle consists in a material having a density of at least 7 g/cm<sup>3</sup> and an atomic number (Z) of at least 25 and each nanoparticle or aggregate of nanoparticles is covered with a biocompatible  
10 coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid.
2. A vaccine composition comprising a nanoparticle and/or aggregate of nanoparticles for use for treating cancer in a subject suffering from metastatic cancer and undergoing a palliative radiotherapy, in a subject suffering from metastatic cancer for whom radiotherapy has been abandoned, in a subject  
15 suffering from a cancer which is not treated by radiotherapy, or in a subject suffering from a liquid cancer, wherein the treatment comprises exposing the subject to a fractionated radiotherapy comprising at least one irradiation step wherein the ionizing radiations dose ranges from 1.8 to 30 Gray (Gy), and wherein each nanoparticle consists in a material having a density of at least 7 g/cm<sup>3</sup> and an atomic number (Z) of at least 25 and each nanoparticle or aggregate of nanoparticles is covered  
20 with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid.
3. The vaccine composition for use according to claim 2 wherein the ionizing radiations dose ranges from 1.8 to 20 Gray (Gy).  
25
4. The vaccine composition for use according to anyone of claims 1 to 3 wherein, when the cancer is a metastatic cancer, the at least one irradiation step is applied *in vivo* on one, at most two, tumor sites of the metastatic cancer comprising the nanoparticles or aggregates of nanoparticles.
- 30 5. The vaccine composition for use according to anyone of claims 1 to 3 wherein, when the cancer is a metastatic cancer, the at least one irradiation step is applied *ex vivo* on a cancer sample of the subject comprising the nanoparticles or aggregates of nanoparticles, and the *ex vivo* lethally irradiated cancer cells and at least part of the associated cell supernatant from the cancer sample are at least partly readministered to the subject before any optional subsequent *in vivo* treatment of cancer in said  
35 subject.

6. The vaccine composition for use according to anyone of claims 1 to 3 wherein, when the cancer is a liquid cancer, the at least one irradiation step is applied *ex vivo* on a liquid cancer sample of the subject comprising the nanoparticles or aggregates of nanoparticles, and the irradiated liquid cancer sample is at least partly readministered to the subject before any optional subsequent *in vivo* treatment of cancer in said subject.

7. The vaccine composition for use according to claim 6 wherein the liquid cancer sample is a blood sample or the whole blood volume of the subject.

8. The vaccine composition for use according to anyone of claims 5 to 7, wherein the *ex vivo* lethally irradiated cancer cells or the irradiated liquid cancer sample is at least partly readministered to the subject together with at least one additional immunotherapeutic agent, the *ex vivo* lethally irradiated cancer cells or the irradiated liquid cancer sample and the least one additional immunotherapeutic agent being administered to the subject either simultaneously or separately.

9. The vaccine composition for use according to anyone of claims 1 to 8, wherein the ionizing radiations dose is selected from 1.8, 2, 2.4, 2.5, 3, 3.2, 3.6, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 15 and 20 Gy per fraction treatment.

10. The vaccine composition for use according to anyone of claims 1 to 9, wherein the metastatic cancer affects (i) a connective tissue and is selected from a fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, malignant fibrous histiocytoma, (ii) an endothelium or mesothelium tissue and is selected from hemangiosarcoma, angiosarcoma, lymphangiosarcoma and mesothelioma, (iii) a muscle tissue and is selected from leiomyosarcoma and rhabdomyosarcoma, (iv) an epithelial tissue and is selected from adenocarcinoma, squamous cell carcinoma and epidermoid carcinoma, (v) a neural tissue and is selected from multiform glioblastoma, glioma, neuroblastoma, medulloblastoma, meningioma, neurofibrosarcoma and schwannoma, and (vi) the APUD system and is selected from thyroid carcinoma, pancreas carcinoma, stomach carcinoma and intestine carcinoma; or wherein the metastatic cancer is a melanoma.

11. The vaccine composition for use according to claim 10 wherein the metastatic cancer is or derives from a cancer selected from skin cancer, central nervous system cancer, head and neck cancer, lung cancer, kidney cancer, breast cancer, gastrointestinal cancer (GIST), prostate cancer, liver cancer, colon cancer, rectum cancer, anal cancer, oesophagus cancer, male genitourinary cancer, gynecologic cancer, adrenal and retroperitoneal cancer, sarcomas of bone and soft tissue, pediatric cancer, neuroblastoma, central nervous system cancer and Ewing's sarcoma.



12. The vaccine composition for use according to anyone of claims 1 to 9, wherein the liquid cancer affects blood or lymphoid cell tissue and is selected from leukemia, myeloma and lymphoma.

13. The vaccine composition for use according to anyone of claims 1 to 12, wherein the nanoparticle or aggregate of nanoparticles are to be administered to the subject to be treated together with at least one immunotherapeutic agent, the nanoparticle or aggregate of nanoparticles and the least one immunotherapeutic agent being administered to the subject either simultaneously or separately.

14. The vaccine composition for use according to anyone of claims 1 to 13, wherein the composition further comprises a pharmaceutically acceptable carrier or vehicle.

15. The vaccine composition for use according to claim 14, wherein the composition further comprises at least one immunotherapeutic agent.

16. A kit comprising (i) a nanoparticle or aggregate of nanoparticles consisting in a material having a density of at least  $7 \text{ g/cm}^3$  and an atomic number (Z) of at least 25, each nanoparticle or aggregate of nanoparticles being covered with a biocompatible coating allowing the nanoparticle stability between pH 6.5 and 7.5 in a physiological fluid, or a composition according to anyone of claims 1-14, together with (ii) at least one immunotherapeutic agent.

17. The vaccine composition for use according to claim 15 or the kit according to claim 16, wherein the at least one immunotherapeutic agent is selected from a monoclonal antibody, a cytokine, and a combination thereof.




FIGURE 1




FIGURE 2




FIGURE 3 A




FIGURE 3 B




FIGURE 3C




FIGURE 4




FIGURE 5






FIGURE 6

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2016/061989

## A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K9/00 A61N5/10 A61K9/51 A61K33/24  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, WPI Data, BIOSIS, FSTA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LAURENCE MAGGIORELLA ET AL: "Nanoscale radiotherapy with hafnium oxide nanoparticles", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB  , vol. 8, no. 9 1 September 2012 (2012-09-01), pages 1167-1181, XP002698557, ISSN: 1479-6694, DOI: 10.2217/FON.12.96 Retrieved from the Internet: URL: <a href="http://www.futuremedicine.com/doi/abs/10.2217/fon.12.96">http://www.futuremedicine.com/doi/abs/10.2217/fon.12.96</a>	1-4, 9-11, 14
Y	Materials; page 1168 page 1175  -----  -/--	1-17



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 July 2016

Date of mailing of the international search report

27/07/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Schüle, Stefanie

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2016/061989

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 2 130 553 A1 (NANOBIOTIX [FR]) 9 December 2009 (2009-12-09)	1-4, 9-12, 14
Y	examples claims	1-17
Y	----- XIAO-DONG ZHANG ET AL: "Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 33, no. 27, 21 May 2012 (2012-05-21), pages 6408-6419, XP028401100, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2012.05.047 [retrieved on 2012-05-24] abstract page 6409, paragraph 2.1 page 6410, paragraph 3.2	1-17
Y	----- WO 2013/087920 A1 (NANOBIOTIX [FR]) 20 June 2013 (2013-06-20) page 7, line 33 - line 35 page 10, line 10 - line 15 page 11, line 14 - line 25 page 15, line 1 - page 16, line 16	1-17
Y	----- LISSETT R BICKFORD ET AL: "Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 120, no. 3, 6 May 2009 (2009-05-06), pages 547-555, XP019787443, ISSN: 1573-7217 the whole document	1-17
Y	----- NATALIE PRAETORIUS ET AL: "Engineered Nanoparticles in Cancer Therapy", RECENT PATENTS ON DRUG DELIVERY & FORMULATION, vol. 1, no. 1, 1 February 2007 (2007-02-01), pages 37-51, XP055107945, NL ISSN: 1872-2113, DOI: 10.2174/187221107779814104 page 39 ----- -/--	1-17

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2016/061989

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>NANOBIOTIX: "Release / Nanobiotix starts clinical trial with lead product NBTXR3", INTERNET CITATION, 13 September 2011 (2011-09-13), XP002671267, Retrieved from the Internet: URL:<a href="http://www.nanobiotix.com/news/release/nanobiotix-starts-clinical-trial-with-lea">http://www.nanobiotix.com/news/release/nanobiotix-starts-clinical-trial-with-lea</a> d-product-nbtxr3/ [retrieved on 2012-03-12] the whole document -----</p>	1-17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2016/061989

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 2130553	A1	09-12-2009	
		AU 2009254550 A1	10-12-2009
		BR PI0913410 A2	24-11-2015
		CA 2727576 A1	10-12-2009
		CN 102056628 A	11-05-2011
		EA 201071429 A1	30-06-2011
		EP 2130553 A1	09-12-2009
		EP 2300054 A2	30-03-2011
		IL 209625 A	30-11-2015
		JP 5734181 B2	17-06-2015
		JP 2011524866 A	08-09-2011
		KR 20110028616 A	21-03-2011
		MA 32453 B1	03-07-2011
		NZ 589888 A	29-06-2012
		SG 10201405288W A	30-10-2014
		US 2011213192 A1	01-09-2011
		WO 2009147214 A2	10-12-2009
		ZA 201100082 B	26-10-2011
WO 2013087920	A1	20-06-2013	
		AU 2012351537 A1	24-07-2014
		CA 2857260 A1	20-06-2013
		CN 104093401 A	08-10-2014
		EA 201491199 A1	28-11-2014
		EP 2790682 A1	22-10-2014
		HK 1203353 A1	30-10-2015
		JP 2015509079 A	26-03-2015
		KR 20140108685 A	12-09-2014
		MA 35851 B1	01-12-2014
		NZ 625848 A	24-04-2015
		SG 11201403096V A	30-07-2014
		US 2014335015 A1	13-11-2014
		WO 2013087920 A1	20-06-2013